$MRKR
Marker Therapeutics, Inc.

2023 Q1 Form 10-K Financial Statement

#000141057823000324 Filed on March 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $4.734M $3.309M $9.014M
YoY Change 390.95% 166.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.516M $1.894M $12.82M
YoY Change -32.61% -36.63% -0.81%
% of Gross Profit
Research & Development $7.271M $5.267M $26.14M
YoY Change 3.48% -34.3% -5.96%
% of Gross Profit
Depreciation & Amortization $818.2K $813.1K $2.789M
YoY Change 41.97% 44.05% 29.79%
% of Gross Profit
Operating Expenses $9.787M $7.161M $38.96M
YoY Change -9.04% -34.94% -4.32%
Operating Profit -$5.052M -$29.95M
YoY Change -48.42% -24.15%
Interest Expense $84.65K $109.4K $248.1K
YoY Change 2613.14% 11179.38% 4251.93%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.968M -$3.856M -$29.93M
YoY Change -49.88% -60.5% -28.53%
Income Tax
% Of Pretax Income
Net Earnings -$4.968M -$3.856M -$29.93M
YoY Change -49.88% -60.5% -28.53%
Net Earnings / Revenue -104.93% -116.54% -332.06%
Basic Earnings Per Share -$0.57 -$3.58
Diluted Earnings Per Share -$0.57 -$0.46 -$3.58
COMMON SHARES
Basic Shares Outstanding 8.799M 83.60M 8.351M
Diluted Shares Outstanding 8.721M 8.351M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.401M $11.78M $11.78M
YoY Change -77.65% -72.18% -72.18%
Cash & Equivalents $6.400M $11.78M $11.78M
Short-Term Investments
Other Short-Term Assets $2.429M $2.435M $2.435M
YoY Change 2.13% -32.93% -32.93%
Inventory
Prepaid Expenses $2.429M $2.435M
Receivables $1.000M
Other Receivables $1.083M $2.402M
Total Short-Term Assets $10.91M $16.62M $16.62M
YoY Change -64.82% -63.86% -63.86%
LONG-TERM ASSETS
Property, Plant & Equipment $11.70M $12.32M $17.80M
YoY Change -18.54% 0.0% -19.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $17.03M $17.80M $17.80M
YoY Change -28.87% -19.64% -19.64%
TOTAL ASSETS
Total Short-Term Assets $10.91M $16.62M $16.62M
Total Long-Term Assets $17.03M $17.80M $17.80M
Total Assets $27.94M $34.42M $34.42M
YoY Change -49.16% -49.48% -49.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.863M $1.612M $2.368M
YoY Change -42.92% -68.66% -53.97%
Accrued Expenses $1.717M $2.914M $2.914M
YoY Change -24.56% -18.36% -18.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.204M $7.782M $7.782M
YoY Change -36.65% -39.68% -39.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.824M $7.039M $7.039M
YoY Change -38.17% -37.42% -37.42%
Total Long-Term Liabilities $6.824M $7.039M $7.039M
YoY Change -38.17% -37.42% -37.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.204M $7.782M $7.782M
Total Long-Term Liabilities $6.824M $7.039M $7.039M
Total Liabilities $12.03M $14.82M $14.82M
YoY Change -37.52% -38.63% -38.63%
SHAREHOLDERS EQUITY
Retained Earnings -$433.0M -$428.0M
YoY Change 6.12% 7.52%
Common Stock $8.799K $8.406K
YoY Change -89.46% -89.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.91M $19.60M $19.60M
YoY Change
Total Liabilities & Shareholders Equity $27.94M $34.42M $34.42M
YoY Change -49.16% -49.48% -49.48%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$4.968M -$3.856M -$29.93M
YoY Change -49.88% -60.5% -28.53%
Depreciation, Depletion And Amortization $818.2K $813.1K $2.789M
YoY Change 41.97% 44.05% 29.79%
Cash From Operating Activities -$5.888M -$6.305M -$26.97M
YoY Change -51.84% 29.79% -1.13%
INVESTING ACTIVITIES
Capital Expenditures $112.6K $127.4K $4.945M
YoY Change -104.59% -136.4% -257.93%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$112.6K -$127.4K -$4.945M
YoY Change -95.41% -63.6% 57.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $202.1K
YoY Change -99.62%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 620.0K 138.6K 202.1K
YoY Change -99.62%
NET CHANGE
Cash From Operating Activities -5.888M -6.305M -26.97M
Cash From Investing Activities -112.6K -127.4K -4.945M
Cash From Financing Activities 620.0K 138.6K 202.1K
Net Change In Cash -5.381M -6.294M 11.80M
YoY Change -118.68% 20.86% -72.87%
FREE CASH FLOW
Cash From Operating Activities -$5.888M -$6.305M -$26.97M
Capital Expenditures $112.6K $127.4K $4.945M
Free Cash Flow -$6.001M -$6.433M -$31.92M
YoY Change -38.6% 42.69% 32.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4704611
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11134913
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001094038
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8300000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8400000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-37939
CY2022 dei Entity Registrant Name
EntityRegistrantName
MARKER THERAPEUTICS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-4497941
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
4551 Kennedy Commerce Drive
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77032
CY2022 dei City Area Code
CityAreaCode
713
CY2022 dei Local Phone Number
LocalPhoneNumber
400-6400
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022 dei Trading Symbol
TradingSymbol
MRKR
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
22800000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8798829
CY2022 dei Auditor Firm
AuditorFirmId
688
CY2022 dei Auditor Name
AuditorName
Marcum LLP
CY2022 dei Auditor Location
AuditorLocation
Houston, TX
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11782172
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42351145
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1146186
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2435079
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2484634
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2402004
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
237
CY2022Q4 us-gaap Assets Current
AssetsCurrent
16619255
CY2021Q4 us-gaap Assets Current
AssetsCurrent
45982202
CY2022Q4 mrkr Property Plant And Equipment Other Than Construction In Progress
PropertyPlantAndEquipmentOtherThanConstructionInProgress
12323143
CY2021Q4 mrkr Property Plant And Equipment Other Than Construction In Progress
PropertyPlantAndEquipmentOtherThanConstructionInProgress
10096861
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
0
CY2021Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2225610
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5479786
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9830461
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
17802929
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
22152932
CY2022Q4 us-gaap Assets
Assets
34422184
CY2021Q4 us-gaap Assets
Assets
68135134
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4704611
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11134913
CY2022Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2500000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1146186
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
577198
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
620490
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7781809
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12901589
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7039338
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11247950
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7039338
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
11247950
CY2022Q4 us-gaap Liabilities
Liabilities
14821147
CY2021Q4 us-gaap Liabilities
Liabilities
24149539
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
15000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8400000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8300000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8406
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
8308
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
447641680
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
442095642
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-428049049
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-398118355
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
19601037
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
43985595
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34422184
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68135134
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9013544
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1241710
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26139323
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27794879
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12820004
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12924826
CY2022 us-gaap Operating Expenses
OperatingExpenses
38959327
CY2021 us-gaap Operating Expenses
OperatingExpenses
40719705
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-29945783
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-39477995
CY2022 mrkr Gain Loss Related To Arbitration Settlement
GainLossRelatedToArbitrationSettlement
-232974
CY2021 mrkr Gain Loss Related To Arbitration Settlement
GainLossRelatedToArbitrationSettlement
-2406576
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
248063
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
5700
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29930694
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41878871
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.58
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.58
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.47
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.47
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8351003
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8351003
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7650567
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7650567
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27344573
CY2022 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3900000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
52552758
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3087
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5964048
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41878871
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
43985595
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
202130
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5344006
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29930694
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
19601037
CY2022 us-gaap Profit Loss
ProfitLoss
-29930694
CY2021 us-gaap Profit Loss
ProfitLoss
-41878871
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2789106
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2148983
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5344006
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
5964048
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
891343
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1013655
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-25995
CY2022 mrkr Gain Loss On Termination Of Leases
GainLossOnTerminationOfLeases
278681
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-49555
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
426710
CY2022 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
2401767
CY2021 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-1000322
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4300939
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4141414
CY2022 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
2500000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1146186
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1146186
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-513891
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-388792
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26972153
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27279765
CY2022 mrkr Payments To Acquire Property Plant And Equipment Excluding Construction In Progress
PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress
1456006
CY2021 mrkr Payments To Acquire Property Plant And Equipment Excluding Construction In Progress
PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress
1572161
CY2022 mrkr Payments For Construction In Progress
PaymentsForConstructionInProgress
3489130
CY2021 mrkr Payments For Construction In Progress
PaymentsForConstructionInProgress
1558970
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4945136
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3131131
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
202130
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52552758
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3087
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
202130
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52555845
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-31715159
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
22144949
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43497331
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21352382
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11782172
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43497331
CY2022 mrkr Reclassifications Between Construction In Progress And Fixed Assets
ReclassificationsBetweenConstructionInProgressAndFixedAssets
4089135
CY2021 mrkr Reclassifications Between Construction In Progress And Fixed Assets
ReclassificationsBetweenConstructionInProgressAndFixedAssets
6789098
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
57607
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2160765
CY2022 mrkr Change To Right Of Use Assets And Lease Liability Due To Close Out Of Operating Lease
ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease
3459332
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1:    NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marker Therapeutics, Inc., a Delaware corporation (the “Company” or “we”), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multiTAA-specific T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reverse Stock Split </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 26, 2023, the Company effected a one-for-ten (1-for-10) reverse stock split of its common stock (the “Reverse Stock Split”) and a corresponding reduction in the total number of authorized shares of its common stock from 300,000,000 to 30,000,000. The Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 24, 2022, was consummated pursuant to a Certificate of Amendment filed with the Secretary of State of Delaware on January 26, 2023. The Reverse Stock Split was effective on January 26, 2023. All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. Payment for fractional shares resulting from the reverse stock split amounted to $394.80.</p>
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11800000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3228286
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52600000
CY2021Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
13100000
CY2021Q3 mrkr Funds Received From Cprit Grant
FundsReceivedFromCpritGrant
4800000
CY2022 mrkr Revenue From Grant Related To Cprit
RevenueFromGrantRelatedToCprit
3400000
CY2022Q3 mrkr Grant Received
GrantReceived
2000000.0
CY2022 mrkr Revenue From Orphan Products Grant Program
RevenueFromOrphanProductsGrantProgram
100000
CY2022Q4 mrkr Orphan Products Grant Program
OrphanProductsGrantProgram
100000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ materially from those estimates. Significant areas requiring management’s estimates and assumptions include measurement of fair value and projections used in impairment testing, valuation allowance on deferred tax assets, determining the fair value of stock-based compensation and stock-based transactions, the fair value of the components of the warrant liabilities and accrued liabilities.</p>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1800000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11782172
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42351145
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1146186
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11782172
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43497331
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1840000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
7617000
CY2022 mrkr Number Of Warrant Expired Or Cancelled
NumberOfWarrantExpiredOrCancelled
135000
CY2022 mrkr Class Of Warrant Or Rights Outstanding Expired Or Cancelled Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice
39.70
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1848000
CY2021Q3 mrkr Receipt Of Product Development Research Award
ReceiptOfProductDevelopmentResearchAward
13100000
CY2021Q4 mrkr Funds Received From Cprit Grant
FundsReceivedFromCpritGrant
2400000
CY2022 mrkr Revenue From Grant Related To Cprit
RevenueFromGrantRelatedToCprit
3400000
CY2022Q4 mrkr Grant Income Receivable
GrantIncomeReceivable
2300000
CY2022 mrkr Revenue From Orphan Products Grant Program
RevenueFromOrphanProductsGrantProgram
100000
CY2022Q4 mrkr Orphan Products Grant Program
OrphanProductsGrantProgram
100000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1983000
CY2021Q4 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
44.20
CY2021 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
P1Y8M12D
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-29930694
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-41878871
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8351003
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8351003
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7650567
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7650567
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.58
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.58
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.47
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.47
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2734000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2751600
CY2022 mrkr Revenue From Orphan Products Grant Program
RevenueFromOrphanProductsGrantProgram
100000
CY2022Q4 mrkr Orphan Products Grant Program
OrphanProductsGrantProgram
100000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
983000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1254000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17597000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12837000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5274000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2740000
CY2022Q4 mrkr Construction In Progress
ConstructionInProgress
0
CY2021Q4 mrkr Construction In Progress
ConstructionInProgress
2226000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12323000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12323000
CY2022 us-gaap Depreciation
Depreciation
2800000
CY2021 us-gaap Depreciation
Depreciation
2100000
CY2022 us-gaap Recapitalization Costs
RecapitalizationCosts
1900000
CY2022Q3 mrkr Decrease In Operating Lease Liabilities For Lease Termination
DecreaseInOperatingLeaseLiabilitiesForLeaseTermination
3700000
CY2022Q3 mrkr Decrease In Operating Lease Right Of Use Assets For Lease Termination
DecreaseInOperatingLeaseRightOfUseAssetsForLeaseTermination
3500000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
7600000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5500000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11900000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9800000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1483000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1702000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
48000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
648000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
606000
CY2022 us-gaap Lease Cost
LeaseCost
2179000
CY2021 us-gaap Lease Cost
LeaseCost
2308000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1106000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1077000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y6M
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y4M24D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.055
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1290000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1177000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1163000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
3590000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9457000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1612000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5144000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1779000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2055000
CY2022Q4 mrkr Accrued Process Development Expenses Current
AccruedProcessDevelopmentExpensesCurrent
342000
CY2021Q4 mrkr Accrued Process Development Expenses Current
AccruedProcessDevelopmentExpensesCurrent
385000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
558000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
644000
CY2021Q4 mrkr Accrued Technology License Fees
AccruedTechnologyLicenseFees
250000
CY2022Q4 mrkr Arbitration Settlement Liabilities Current
ArbitrationSettlementLiabilitiesCurrent
114000
CY2021Q4 mrkr Arbitration Settlement Liabilities Current
ArbitrationSettlementLiabilitiesCurrent
2407000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
300000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
250000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 mrkr Offering Cost
OfferingCost
3900000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2083000
CY2020 mrkr Class Of Warrant Or Rights Outstanding Exercised Weighted Average Exercised For Cash
ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash
47.00
CY2020 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
P2Y7M6D
CY2021 mrkr Number Of Warrant Expired Or Cancelled
NumberOfWarrantExpiredOrCancelled
100000
CY2021 mrkr Class Of Warrant Or Rights Outstanding Expired Or Cancelled Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice
55.00
CY2022Q4 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
44.51
CY2022 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
P0Y9M14D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P1Y
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
600181
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
62.18
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
191500
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
28.97
CY2021 mrkr Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted In Period Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
P8Y10M24D
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
146
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
21.20
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
22912
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
35.92
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
768623
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
54.69
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
260000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.68
CY2022 mrkr Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted In Period Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
P7Y9M18D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
142450
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
36.78
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
886173
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.90
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
560929
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
59.39
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
4.70
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
29.00
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.85
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.94
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.02
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.01
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-8769000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5344000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5964000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3500000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2021Q3 mrkr Receipt Of Product Development Research Award
ReceiptOfProductDevelopmentResearchAward
13100000
CY2022Q4 mrkr Grant Income Receivable
GrantIncomeReceivable
2300000
CY2023Q1 mrkr Funds Received From Grant
FundsReceivedFromGrant
2400000
CY2022 mrkr Revenue From Orphan Products Grant Program
RevenueFromOrphanProductsGrantProgram
100000
CY2022Q4 mrkr Orphan Products Grant Program
OrphanProductsGrantProgram
100000
CY2022 mrkr Compensation Interest And Attorney Fees
CompensationInterestAndAttorneyFees
2400000
CY2021Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
2400000
CY2021 us-gaap Other Expenses
OtherExpenses
2400000
CY2022Q1 mrkr Legal Proceedings Broker Awarded Additional Interest Amount
LegalProceedingsBrokerAwardedAdditionalInterestAmount
100000
CY2022Q1 mrkr Percentage Of Accrual Of Post Judgment Interest
PercentageOfAccrualOfPostJudgmentInterest
0.0102
CY2022Q1 mrkr Broker Was Awarded Accrued Interest
BrokerWasAwardedAccruedInterest
2500000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2094
CY2022 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
1019000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0340
CY2021 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
103000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0025
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2022 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
1508000
CY2021 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
3437000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
30072000
CY2022Q4 mrkr Deferredtaxstockbasedcompensation
Deferredtaxstockbasedcompensation
5642000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4818000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
733000
CY2022Q4 mrkr Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
1611000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42876000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
41413000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1463000
CY2022Q4 mrkr Deferred Tax Liabilities Fixed Assets
DeferredTaxLiabilitiesFixedAssets
304000
CY2022Q4 mrkr Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
1159000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1463000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
733000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
135200000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
38500000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
41600000
CY2022 mrkr Taxcreditcarryforwardexpirationyearrangestart
Taxcreditcarryforwardexpirationyearrangestart
2029
CY2022 mrkr Taxcreditcarryforwardexpirationyearrangeend
Taxcreditcarryforwardexpirationyearrangeend
2037
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
21900000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6285000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8795000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-44000
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0015
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-48000
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0011
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
10000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.0003
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-291000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0069
CY2022 mrkr Permanentdifferencesotherpermanentdifferences
Permanentdifferencesotherpermanentdifferences
-288000
CY2022 mrkr Effective Income Tax Rate Reconciliation Other Permanent Differences
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
-0.0096
CY2021 mrkr Permanentdifferencesotherpermanentdifferences
Permanentdifferencesotherpermanentdifferences
-262000
CY2021 mrkr Effective Income Tax Rate Reconciliation Other Permanent Differences
EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences
-0.0063
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-5012000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1675
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0001410578-23-000324-index-headers.html Edgar Link pending
0001410578-23-000324-index.html Edgar Link pending
0001410578-23-000324.txt Edgar Link pending
0001410578-23-000324-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrkr-20221231.xsd Edgar Link pending
mrkr-20221231x10k.htm Edgar Link pending
mrkr-20221231x10k001.jpg Edgar Link pending
mrkr-20221231x10k002.jpg Edgar Link pending
mrkr-20221231x10k003.jpg Edgar Link pending
mrkr-20221231x10k004.jpg Edgar Link pending
mrkr-20221231x10k005.jpg Edgar Link pending
mrkr-20221231x10k006.jpg Edgar Link pending
mrkr-20221231x10k007.jpg Edgar Link pending
mrkr-20221231x10k008.jpg Edgar Link pending
mrkr-20221231x10k009.jpg Edgar Link pending
mrkr-20221231x10k010.jpg Edgar Link pending
mrkr-20221231x10k011.jpg Edgar Link pending
mrkr-20221231xex21d1.htm Edgar Link pending
mrkr-20221231xex23d1.htm Edgar Link pending
mrkr-20221231xex31d1.htm Edgar Link pending
mrkr-20221231xex31d2.htm Edgar Link pending
mrkr-20221231xex32d1.htm Edgar Link pending
mrkr-20221231xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
mrkr-20221231_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
mrkr-20221231_def.xml Edgar Link unprocessable
mrkr-20221231_lab.xml Edgar Link unprocessable
mrkr-20221231_pre.xml Edgar Link unprocessable
mrkr-20221231x10k_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending